TLX

Profile

Full Name

Telix Pharmaceuticals Limited

Ticker Symbol

TLX

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

Australia

IPO

November 14, 2024

Indexes

Not included

Website

http://telixpharma.com

Employees

-

Key Details

Price

$18.80(-2.19%)

Market cap

$6.29B(Mid cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$516.67M(+54.86% YoY)

Annual EPS

$0.10(+791.59% YoY)

PE ratio

-

Next earnings date

Aug 22, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$18.80
TLX price is $18.80

30-Day Relative Volume

1.12
TLX 30-day relative volume is 1.12

Price Performance

Price Most recent change

-2.19%
TLX price was down -2.19% on Apr 25, 2025

Price YTD change

+22.08%
TLX price is up +22.08% since January 1st

Price 1-year change

-
TLX price 1-year change is unknown

Price 3-year change

-
TLX price 3-year change is unknown

Price Range

Price All-time high

$30.36
TLX price is currently -38.08% below its historical high of $30.36

Price 3-year low

$13.61
TLX price is currently +38.13% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$6.29B
TLX market capitalization is $6.29 billion

Market cap 3-year change

-
TLX market capitalization 3-year change is unknown

Market cap All-time high

$6.83B
TLX market capitalization is currently -7.80% below its historical high of $6.83 billion

Market cap sector rank

90.22%
TLX market capitalization is higher than 90.22% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+1.29%
TLX shares outstanding is up +1.29% year-on-year

Shares Outstanding 3-Year Change

+7.2%
TLX shares outstanding is up +7.2% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.91
TLX beta is 0.91

200-day SMA

$16.80
TLX price is currently +11.93% above its 200-day simple moving average

50-day SMA

$17.38
TLX price is currently +8.18% above its 50-day simple moving average

RSI

62.04
TLX 14-day relative strength index is 62.04

Volume

1.12
TLX 30-day relative volume is 1.12

ATR

$0.98
TLX average true range is $0.98

10-day Historical Volatility

60.22%
TLX 10-day historical volatility is 60.22%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$516.67M
TLX annual revenue is $516.67 million

Revenue Analysts estimate

$1.28B
TLX annual revenue is currently -59.53% lower than the consensus analysts' forecast

Revenue 1-year change

+54.86%
TLX annual revenue is up +54.86% year-on-year

Revenue Sector rank

74.29%
TLX annual revenue is higher than 74.29% of companies in Healthcare sector

EPS

EPS

$0.10
TLX annual earnings per share is $0.10

EPS Analysts estimate

$0.36
TLX annual earnings per share is currently -73.51% lower than the consensus analysts' forecast

EPS 1-year change

+791.59%
TLX annual earnings per share is up +791.59% year-on-year

EPS Sector rank

83.31%
TLX annual earnings per share is higher than 83.31% of companies in Healthcare sector

Profit

Gross profit

$336.23M
TLX annual gross profit is $336.23 million

Gross margin

65.08%
TLX annual gross profit margin is 65.08%

Operating profit

$53.73M
TLX annual operating income is $53.73 million

Operating margin

10.40%
TLX annual operating profit margin is 10.40%

Net income

$32.93M
TLX annual net profit is $32.93 million

Net margin

6.37%
TLX annual net profit margin is 6.37%

Expenses

Total expenses

$462.93M
TLX annual total expenses is $462.93 million

Operating expenses

$282.49M
TLX annual total operating expenses is $282.49 million

Cost of goods sold

$180.44M
TLX annual cost of goods sold is $180.44 million

Selling, general & administrative expenses

$153.61M
TLX annual SGA is $153.61 million

Depreciation and amortization

-
TLX annual depreciation & amortization value is unknown

Interest expense

$24.07M
TLX annual interest expense is $24.07 million

Income tax

$4.05M
TLX annual income tax is $4.05 million

EBIT & EBITDA

EBIT

$61.05M
TLX annual earnings before interest & taxes is $61.05 million

EBITDA

$61.05M
TLX annual EBITDA is $61.05 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$942.96M
TLX annual total assets is $942.96 million

Non current assets

$371.77M
TLX annual long term assets is $371.77 million

Current assets

$571.19M
TLX annual total current assets is $571.19 million

Cash and cash equivalents

$441.71M
TLX annual cash & cash equivalents is $441.71 million

Accounts receivable

$86.71M
TLX annual accounts receivable is $86.71 million

Inventory

$23.72M
TLX annual inventory is $23.72 million

Liabilities

Total liabilities

$589.63M
TLX annual total liabilities is $589.63 million

Long term liabilities

$383.86M
TLX annual total long term liabilities is $383.86 million

Current liabilities

$205.77M
TLX annual total current liabilities is $205.77 million

Accounts payable

$42.72M
TLX annual accounts payable is $42.72 million

Debt

Total debt

$361.56M
TLX annual total debt is $361.56 million

Total debt 1-year change

+2942.12%
TLX annual total debt is up +2942.12% year-on-year

Long term debt

$348.20M
TLX annual long term debt is $348.20 million

Short term debt

$13.36M
TLX annual short term debt is $13.36 million

Equity & Capital

Shareholders equity

$353.33M
TLX annual stockholders equity is $353.33 million

Book value

$353.33M
TLX annual book value is $353.33 million

Retained earnings

-$132.43M
TLX annual retained earnings is -$132.43 million

Working capital

$365.42M
TLX annual working capital is $365.42 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-
TLX annual cash flow from operations value is unknown

Cash from operations 1-year change

-
TLX annual cash flow from operations 1-year change is unknown

Cash from investing

-$89.17M
TLX annual cash flow from investing activities is -$89.17 million

Cash from investing 1-year change

-426.97%
TLX annual cash flow from investing activities is down -426.97% year-on-year

Cash from financing

$421.49M
TLX annual cash flow from financing activities is $421.49 million

Cash from financing 1-year change

+6132.88%
TLX annual cash flow from financing activities is up +6132.88% year-on-year

CAPEX

CAPEX

$22.45M
TLX annual capital expenditures is $22.45 million

CAPEX 1-year change

+213.29%
TLX annual capital expenditures is up +213.29% year-on-year

Free Cash Flow

Free cash flow

-
TLX annual free cash flow value is unknown

Free cash flow 1-year change

-
TLX annual free cash flow 1-year change is unknown

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

65.08%
TLX annual gross profit margin is 65.08%

Operating margin

10.40%
TLX annual operating profit margin is 10.40%

Net margin

6.37%
TLX annual net profit margin is 6.37%

ROA & ROE

ROA

5.40%
TLX annual return on assets is 5.40%

ROE

14.48%
TLX annual return on equity is 14.48%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
TLX price to earnings ratio value is unknown

PE ratio Sector rank

-
TLX price to earnings ratio is unknown

PB Ratio

PB ratio

17.81
TLX price to book ratio is 17.81

PB ratio Sector rank

96.26%
TLX price to book ratio is higher than 96.26% of companies in Healthcare sector

PS Ratio

PS ratio

-
TLX price to sales ratio value is unknown

PS ratio Sector rank

-
TLX price to sales ratio is unknown

Enterprise value

Enterprise value

$6.21B
TLX enterprise value is $6.21 billion

Enterprise value Sector rank

89.41%
TLX enterprise value is higher than 89.41% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-
TLX EV/EBITDA value is unknown

EV/EBITDA Sector rank

-
TLX EV/EBITDA is unknown

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

2.78
TLX annual current ratio is 2.78

Quick ratio

2.66
TLX annual quick ratio is 2.66

Leverage

Debt to equity

1.00
TLX annual debt to equity ratio is 1.00

Interest coverage ratio

2.54
TLX annual interest coverage ratio is 2.54

Risk & Stability

Piotroski F-Score

-
TLX piotroski f-score value is unknown

Altman Z-Score

7.43
TLX altman z-score is 7.43

Analyst ratings

Recent major analysts updates

Jan 27, 25 UBS
Buy
Nov 15, 24 UBS
Buy

Institutional Ownership

Similar stocks

LEGN logo
Legend Biotech (LEGN)
TFX logo
Teleflex Incorporated (TFX)
WAY logo
Waystar Holding (WAY)
TGTX logo
TG Therapeutics (TGTX)
GH logo
Guardant Health (GH)
BRKR logo
Bruker (BRKR)
STVN logo
Stevanato Group SpA (STVN)
SRPT logo
Sarepta Therapeutics (SRPT)
CRL logo
Charles River Laboratories International (CRL)
  • What is the ticker symbol for Telix Pharmaceuticals Limited?
  • Does Telix Pharmaceuticals Limited pay dividends?
  • What sector is Telix Pharmaceuticals Limited in?
  • What industry is Telix Pharmaceuticals Limited in?
  • What country is Telix Pharmaceuticals Limited based in?
  • When did Telix Pharmaceuticals Limited go public?
  • Is Telix Pharmaceuticals Limited in the S&P 500?
  • Is Telix Pharmaceuticals Limited in the NASDAQ 100?
  • Is Telix Pharmaceuticals Limited in the Dow Jones?
  • When was Telix Pharmaceuticals Limited's last earnings report?
  • When does Telix Pharmaceuticals Limited report earnings?

What is the ticker symbol for Telix Pharmaceuticals Limited?

The ticker symbol for Telix Pharmaceuticals Limited is NASDAQ:TLX

Does Telix Pharmaceuticals Limited pay dividends?

No, Telix Pharmaceuticals Limited does not pay dividends

What sector is Telix Pharmaceuticals Limited in?

Telix Pharmaceuticals Limited is in the Healthcare sector

What industry is Telix Pharmaceuticals Limited in?

Telix Pharmaceuticals Limited is in the Biotechnology industry

What country is Telix Pharmaceuticals Limited based in?

Telix Pharmaceuticals Limited is headquartered in Australia

When did Telix Pharmaceuticals Limited go public?

Telix Pharmaceuticals Limited's initial public offering (IPO) was on November 14, 2024

Is Telix Pharmaceuticals Limited in the S&P 500?

No, Telix Pharmaceuticals Limited is not included in the S&P 500 index

Is Telix Pharmaceuticals Limited in the NASDAQ 100?

No, Telix Pharmaceuticals Limited is not included in the NASDAQ 100 index

Is Telix Pharmaceuticals Limited in the Dow Jones?

No, Telix Pharmaceuticals Limited is not included in the Dow Jones index

When was Telix Pharmaceuticals Limited's last earnings report?

Telix Pharmaceuticals Limited's most recent earnings report was on Feb 20, 2025

When does Telix Pharmaceuticals Limited report earnings?

The next expected earnings date for Telix Pharmaceuticals Limited is Aug 22, 2025
On this page